Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.

Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...

One patient with TNBC describes the challenges she faced trying to de-escalate a grueling treatment regimen despite warnings ...

A recent review and meta-analysis of probiotics for asthma showed probiotics’ potential in managing asthma by reducing ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Dish soap is a great tool, but it's not the solution for every cleaning task. CR fills you in what you shouldn't clean with dish soap.

In an exclusive conversation with International Business Times, India, Rozlyn Khan questioned the authenticity of Hina Khan's ...

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd ("Kelun-Biotech" will present efficacy and safety results from the ...